[go: up one dir, main page]

NL301207I1 - tezepelumab - Google Patents

tezepelumab

Info

Publication number
NL301207I1
NL301207I1 NL301207C NL301207C NL301207I1 NL 301207 I1 NL301207 I1 NL 301207I1 NL 301207 C NL301207 C NL 301207C NL 301207 C NL301207 C NL 301207C NL 301207 I1 NL301207 I1 NL 301207I1
Authority
NL
Netherlands
Prior art keywords
tezepelumab
Prior art date
Application number
NL301207C
Other languages
English (en)
Other versions
NL301207I2 (nl
Inventor
Bo-Rin P Yoon
Michael R Comeau
Christopher Mehlin
James F Smothers
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40242598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301207(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NL301207I1 publication Critical patent/NL301207I1/nl
Publication of NL301207I2 publication Critical patent/NL301207I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NL301207C 2007-09-10 2022-12-12 tezepelumab NL301207I2 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97117807P 2007-09-10 2007-09-10
US9167608P 2008-08-25 2008-08-25
PCT/US2008/010510 WO2009035577A1 (en) 2007-09-10 2008-09-09 Antigen binding proteins capable of binding thymic stromal lymphopoietin

Publications (2)

Publication Number Publication Date
NL301207I1 true NL301207I1 (nl) 2022-12-21
NL301207I2 NL301207I2 (nl) 2023-02-02

Family

ID=40242598

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301207C NL301207I2 (nl) 2007-09-10 2022-12-12 tezepelumab

Country Status (36)

Country Link
US (5) US7982016B2 (nl)
EP (3) EP2205635B1 (nl)
JP (8) JP5956716B2 (nl)
KR (2) KR20140141666A (nl)
CN (2) CN101809035B (nl)
AR (1) AR068508A1 (nl)
AU (1) AU2008300028B2 (nl)
CA (1) CA2698382C (nl)
CL (2) CL2008002668A1 (nl)
CR (2) CR11319A (nl)
CY (2) CY1117702T1 (nl)
DK (1) DK2205635T3 (nl)
EA (2) EA201590631A1 (nl)
ES (1) ES2581229T3 (nl)
FR (1) FR22C1059I2 (nl)
HK (1) HK1145843A1 (nl)
HR (1) HRP20160638T1 (nl)
HU (2) HUE028361T2 (nl)
IL (3) IL204069A (nl)
JO (1) JO3351B1 (nl)
LT (1) LT2205635T (nl)
MX (1) MX2010002590A (nl)
MY (1) MY150242A (nl)
NL (1) NL301207I2 (nl)
NO (1) NO2022055I1 (nl)
NZ (1) NZ583933A (nl)
PE (2) PE20110668A1 (nl)
PH (1) PH12017501025B1 (nl)
PL (1) PL2205635T3 (nl)
PT (1) PT2205635T (nl)
RS (1) RS54950B1 (nl)
SG (2) SG10201506251YA (nl)
SI (1) SI2205635T1 (nl)
TW (2) TW201412774A (nl)
WO (1) WO2009035577A1 (nl)
ZA (1) ZA201001895B (nl)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
BRPI0720271A2 (pt) 2006-12-14 2014-01-28 Schering Corp Anticorpo anti-tslp projetado
EP2574628B1 (en) 2008-01-25 2015-05-20 Amgen Inc. Ferroportin antibodies and methods of use
US8637019B2 (en) 2009-11-04 2014-01-28 Merck Sharp & Dohme Corp. Engineered anti-TSLP antibody
EP2725034B1 (en) * 2010-09-22 2019-04-03 Amgen Inc. Carrier immunoglobulins with no specificity for human tissues and uses thereof
US9732151B2 (en) * 2011-11-03 2017-08-15 Merck Sharp & Dohme Corp. Biomarkers for TSLP treatment
BR112014026531B1 (pt) * 2012-04-27 2023-10-03 Novo Nordisk A/S Anticorpos isolados que se ligam a cd30l, e composição farmacêutica
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
CN104371019B (zh) * 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
EP3712166A1 (en) 2013-09-05 2020-09-23 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
WO2015118124A1 (en) * 2014-02-06 2015-08-13 Vib Vzw Thymic stromal lymphopoietin receptor antagonist
EP3139977B1 (en) 2014-05-07 2021-02-17 Amgen Inc. Autoinjector with shock reducing elements
WO2015175861A1 (en) 2014-05-16 2015-11-19 Amgen Inc. Assay for detecting th1 and th2 cell populations
EP3151883A1 (en) 2014-06-03 2017-04-12 Amgen Inc. Devices and methods for assisting a user of a drug delivery device
AU2015332557B2 (en) 2014-10-14 2020-05-14 Amgen Inc. Drug injection device with visual and audio indicators
WO2016065181A1 (en) 2014-10-23 2016-04-28 Amgen Inc. Reducing viscosity of pharmaceutical formulations
JP2017538512A (ja) 2014-12-19 2017-12-28 アムジエン・インコーポレーテツド ライブボタンまたはユーザインタフェースフィールドを含む薬物送達装置
EP3556411B1 (en) 2015-02-17 2021-06-30 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3981450A1 (en) 2015-02-27 2022-04-13 Amgen, Inc Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
AR103891A1 (es) * 2015-03-11 2017-06-14 Glaxosmithkline Ip Dev Ltd Proteínas de unión a tslp, ácido nucleico aislado que la codifica, vector y célula hospedadora que lo comprenden, método para producir dicha proteína, su uso para fabricar un medicamento, composición farmacéutica y kit que la comprenden
CN111234027A (zh) * 2015-05-21 2020-06-05 哈普恩治疗公司 三特异性结合蛋白质及使用方法
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
EA038332B1 (ru) * 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
EP3842457A1 (en) 2015-09-09 2021-06-30 Novartis AG Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
US11351308B2 (en) 2015-12-09 2022-06-07 Amgen Inc. Auto-injector with signaling cap
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
EP3405498A1 (en) 2016-01-22 2018-11-28 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies
GB201615588D0 (en) * 2016-09-14 2016-10-26 Glaxosmithkline Ip Dev Ltd TSLP Binding Proteins
US11200298B2 (en) 2016-03-15 2021-12-14 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
WO2017174556A1 (en) 2016-04-05 2017-10-12 Vib Vzw Novel tslp inhibitors
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
ES2959783T3 (es) 2016-05-13 2024-02-28 Amgen Inc Conjunto de cubierta protectora de vial
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
MX2018015757A (es) 2016-06-14 2019-05-30 Merck Sharp & Dohme Anticuerpos antifactor de la coagulacion xi.
US11285266B2 (en) 2016-07-01 2022-03-29 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
EP3495391A4 (en) * 2016-08-05 2020-08-19 Y-Biologics Inc. ANTIBODIES AGAINST PROGRAMMED DEATH LIGAND 1 (PD-L1) AND USE OF IT
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
AU2018210301A1 (en) 2017-01-17 2019-08-01 Amgen Inc. Injection devices and related methods of use and assembly
CN109476755B (zh) 2017-01-24 2020-12-04 天境生物科技(上海)有限公司 Cd73抗体及其用途
US11369736B2 (en) 2017-02-17 2022-06-28 Amgen Inc. Cannula insertion and retraction mechanisms
JP7064501B2 (ja) 2017-02-17 2022-05-10 アムジエン・インコーポレーテツド 無菌流体流路を備える薬物送達デバイスおよび関連する組立方法
AU2018231107B2 (en) 2017-03-06 2023-04-20 Amgen Inc. Drug delivery device with activation prevention feature
CA3052482A1 (en) 2017-03-07 2018-09-13 Amgen Inc. Needle insertion by overpressure
KR20240005194A (ko) 2017-03-09 2024-01-11 암겐 인코포레이티드 약물 전달 장치용 삽입 메커니즘
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
LT3600491T (lt) 2017-03-28 2023-10-10 Amgen Inc. Stūmoklio koto ir švirkšto konstrukcinė sistema ir būdas
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
MA48464A (fr) 2017-04-28 2020-03-04 Amgen Inc Dipeptides n-acétylés et non acétylés contenant de l'arginine destinés à réduire la viscosité de compositions visqueuses de polypeptides thérapeutiques
WO2018226565A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
US11541183B2 (en) 2017-06-22 2023-01-03 Amgen Inc. Device activation impact/shock reduction
CA3063921A1 (en) 2017-06-23 2018-12-27 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
CN109206514B (zh) * 2017-07-03 2019-10-08 拜西欧斯（北京）生物技术有限公司 Tslp单克隆抗体及其制备方法和应用
MA49562A (fr) 2017-07-14 2020-05-20 Amgen Inc Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
US11672733B2 (en) 2017-07-21 2023-06-13 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
EP3658206A1 (en) 2017-07-25 2020-06-03 Amgen Inc. Drug delivery device with container access system and related method of assembly
EP3658203B1 (en) 2017-07-25 2022-08-31 Amgen Inc. Drug delivery device with gear module and related method of assembly
KR102577670B1 (ko) 2017-08-01 2023-09-12 암젠 인크 샘플의 실시간 글리칸 분석을 수행하기 위한 시스템 및 방법
JP7237022B2 (ja) 2017-08-01 2023-03-10 アムジエン・インコーポレーテツド 質量分析法による分析用ポリペプチド試料のリアルタイム調製のためのシステム及び方法
US20200164155A1 (en) 2017-08-09 2020-05-28 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
EP3669004A1 (en) 2017-08-16 2020-06-24 Medimmune, LLC Compositions and methods for treatment of atopic dermatitis and treatment selection
EP3668567A1 (en) 2017-08-18 2020-06-24 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
US11813426B2 (en) 2017-10-06 2023-11-14 Amgen Inc. Drug delivery device including seal member for needle of syringe
EP3694578A1 (en) 2017-10-09 2020-08-19 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
MA50528A (fr) 2017-11-03 2020-09-09 Amgen Inc Systèmes et approches pour stériliser un dispositif d'administration de médicament
MA50569A (fr) 2017-11-06 2020-09-16 Amgen Inc Ensembles de remplissage-finition et procédés associés
AU2018358749B2 (en) 2017-11-06 2024-02-29 Amgen Inc. Drug delivery device with placement and flow sensing
US11191904B2 (en) 2017-11-10 2021-12-07 Amgen Inc. Plungers for drug delivery devices
JP7370969B2 (ja) 2017-11-16 2023-10-30 アムジエン・インコーポレーテツド 薬物送達デバイスの扉ラッチ機構
MA52015A (fr) 2018-03-13 2021-01-20 Amgen Inc Digestion séquentielle de polypeptides pour une analyse par spectrométrie de masse
US20210041453A1 (en) 2018-03-13 2021-02-11 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
IL313983A (en) 2018-03-26 2024-08-01 Amgen Inc Total afucosylated glycoforms of antibodies produced in cell culture
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023444A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
US20210260279A1 (en) 2018-07-24 2021-08-26 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
WO2020023451A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
IL279323B1 (en) 2018-07-31 2025-01-01 Amgen Inc Assembling a fluid pathway for a drug delivery device
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
WO2020068623A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
BR112021005769A2 (pt) 2018-09-25 2021-07-06 Harpoon Therapeutics Inc proteínas de ligação a dll3 e métodos de uso
EP3856283A1 (en) 2018-09-28 2021-08-04 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
MA53815A (fr) 2018-10-02 2022-01-05 Amgen Inc Systèmes d'injection pour administration de médicament avec transmission de force interne
MX2021003491A (es) 2018-10-05 2021-06-18 Amgen Inc Dispositivo de administracion de farmacos con indicador de dosis.
TWI846741B (zh) 2018-10-15 2024-07-01 美商安進公司 用於藥物遞送裝置之平台組裝方法
US12053617B2 (en) 2018-10-15 2024-08-06 Amgen Inc. Drug delivery device having damping mechanism
IL281908B1 (en) 2018-11-01 2025-02-01 Amgen Inc Drug delivery devices with partial drug delivery unit withdrawal
US11213620B2 (en) 2018-11-01 2022-01-04 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
CA3126018A1 (en) 2018-12-14 2020-06-18 Amgen Inc. System suitability method for use with protein concentration determination by slope
US11452738B2 (en) 2019-01-04 2022-09-27 Empirico Inc. Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts
WO2020168156A1 (en) 2019-02-14 2020-08-20 Amgen Inc. Systems and methods for preparing a sample and performing a real-time assay of the sample
CA3127817A1 (en) 2019-02-20 2020-08-27 Amgen Inc. Methods of determining protein stability
EP3935396A1 (en) 2019-03-04 2022-01-12 Amgen Inc. In vivo reversibility of high molecular weight species
CA3133459A1 (en) 2019-03-27 2020-10-01 Amgen Inc. Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
EP3958934A1 (en) 2019-04-24 2022-03-02 Amgen Inc. Syringe sterilization verification assemblies and methods
TW202110882A (zh) 2019-06-04 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 能結合胸腺基質淋巴細胞生成素的抗體及其應用
CA3138941A1 (en) 2019-06-05 2020-12-10 Amgen Inc. Methods of identifying attributes of therapeutic proteins
WO2021041067A2 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
KR20220069982A (ko) 2019-09-26 2022-05-27 암젠 인크 항체 조성물의 생산 방법
PH12022551022A1 (en) * 2019-10-28 2023-03-06 Medimmune Ltd Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
CN114887053A (zh) * 2019-11-29 2022-08-12 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
MX2022004919A (es) * 2019-12-13 2022-05-16 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Anticuerpo anti-linfopoyetina estromal timica (tslp) y sus usos.
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CN111171150B (zh) * 2020-02-05 2020-12-08 北京智仁美博生物科技有限公司 抗人tslp抗体及其用途
EP4103605A1 (en) 2020-02-13 2022-12-21 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
EP4103235A1 (en) 2020-02-13 2022-12-21 Amgen Inc. Formulations of human anti-tslp antibodies and methods of treating inflammatory disease
PE20230115A1 (es) 2020-02-18 2023-01-27 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos
CN111662379B (zh) * 2020-05-09 2021-03-02 江苏省疾病预防控制中心(江苏省公共卫生研究院) 抗新型冠状病毒的抗体、制备方法和应用
MX2022014420A (es) * 2020-05-20 2023-03-21 Univ Columbia Potentes anticuerpos neutralizantes contra el sars-cov-2, generacion y usos de los mismos.
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
JP2023543167A (ja) 2020-09-18 2023-10-13 アムジエン・インコーポレーテツド ペプチドマッピング分析のための試料を処理する方法
CA3197930A1 (en) 2020-10-15 2022-04-21 Amgen Inc. Relative unpaired glycans in antibody production methods
AU2021376246A1 (en) 2020-11-05 2023-06-08 Amgen Inc. Materials and methods for protein processing
CN114437212B (zh) * 2020-11-06 2023-03-14 上海麦济生物技术有限公司 抗人胸腺基质淋巴细胞生成素抗体及其制备方法和应用
WO2022117079A1 (zh) * 2020-12-03 2022-06-09 江苏恒瑞医药股份有限公司 结合胸腺基质淋巴细胞生成素的抗体及其应用
CN113501878B (zh) 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
CN115210258A (zh) * 2021-02-04 2022-10-18 舒泰神（北京）生物制药股份有限公司 特异性识别胸腺基质淋巴细胞生成素的抗体及其用途
US20240190951A1 (en) 2021-04-23 2024-06-13 Amgen Inc. Anti-tslp antibody compositions and uses thereof
US20240182558A1 (en) 2021-04-23 2024-06-06 Amgen Inc. Modified anti-tslp antibodies
MX2023013640A (es) 2021-05-21 2023-11-30 Amgen Inc Metodo de optimizacion de una receta de llenado para un contenedor de medicamento.
KR20240017006A (ko) * 2021-05-30 2024-02-06 바이오로직 디자인 리미티드 조작된 이중 결합 항체 및 이의 용도
CN113069543B (zh) * 2021-06-07 2021-08-06 迈威(上海)生物科技股份有限公司 包含抗胸腺基质淋巴细胞生成素的单克隆抗体的液体组合物
CA3222409A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
CN113683694B (zh) 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
WO2023059607A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023070948A1 (zh) * 2021-11-01 2023-05-04 江苏荃信生物医药股份有限公司 包含抗人胸腺基质淋巴细胞生成素(tslp)单克隆抗体的浓缩溶液的制备方法及液体制剂
CA3237662A1 (en) 2021-11-09 2023-05-19 Amgen Inc. Production of therapeutic proteins
CN116217724B (zh) * 2021-12-02 2023-10-27 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN114369654B (zh) * 2021-12-21 2023-11-07 广州市妇女儿童医疗中心 川崎病的生物标志物及其应用
JP2025500971A (ja) * 2021-12-24 2025-01-15 インマージーン プライベート リミテッド 新規の抗ｔｓｌｐ抗体
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
US12110324B2 (en) * 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
CN118580343A (zh) * 2022-10-21 2024-09-03 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
WO2024092064A1 (en) 2022-10-26 2024-05-02 Amgen Inc. Anti-tslp antibody compositions and uses thereof
WO2024163978A2 (en) 2023-02-02 2024-08-08 Medimmune, Llc Treatment of chronic rhinosinusitis with anti-tslp antibody
WO2024174895A1 (zh) * 2023-02-23 2024-08-29 四川科伦博泰生物医药股份有限公司 一种靶向tslp的单克隆抗体制剂
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content
WO2024238877A1 (en) 2023-05-18 2024-11-21 Medimmune, Llc Treatment of corticosteroid dependent asthma with anti-tslp antibody
WO2024259275A1 (en) 2023-06-14 2024-12-19 Bristol-Myers Squibb Company Near real time sialic acid quantitation of glycoproteins

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
JPS58117537A (ja) 1982-01-06 1983-07-13 Toray Ind Inc 感光性樹脂組成物
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU629958B2 (en) 1989-06-15 1992-10-15 Immunex Corporation Interleukin-7 receptors
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP0639079B1 (en) 1992-04-30 2000-01-12 Amgen Inc. Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
DK0672141T3 (da) 1992-10-23 2003-06-10 Immunex Corp Fremgangsmåder til fremstilling af opløselige, oligomere proteiner
EP0737071A1 (en) 1993-06-15 1996-10-16 Il- Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
GB9702944D0 (en) 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
ATE386802T1 (de) 1997-06-12 2008-03-15 Novartis Int Pharm Ltd Künstliche antikörperpolypeptide
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6844170B1 (en) 1998-03-19 2005-01-18 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
EP1982990A1 (en) 1998-03-19 2008-10-22 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
WO2000017362A1 (en) 1998-09-21 2000-03-30 Schering Corporation Human interleukin-b50, therapeutic uses
US20030099947A1 (en) 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
DE69936105T3 (de) 1998-11-13 2017-07-27 Immunex Corporation Menschliche tslp nukleinsäuren und polypeptide
WO2000039149A2 (en) 1998-12-30 2000-07-06 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
EP1712239A3 (en) 2000-05-12 2007-08-22 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
US6955895B2 (en) 2000-06-28 2005-10-18 Whitehead Institute For Biomedical Research Thymic stromal lymphopoietin receptor molecules and uses thereof
EP1294879B1 (en) 2000-06-28 2008-12-31 Amgen Inc. Thymic stromal lymphopoietin receptor molecules and uses thereof
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CN1234728C (zh) * 2001-05-16 2006-01-04 上海睿星基因技术有限公司 新的人淋巴因子、其编码序列及用途
EP2298809A3 (en) 2001-07-12 2012-02-15 FOOTE, Jefferson Super humanized antibodies
CA2454578C (en) 2001-07-23 2013-06-25 Immunex Corporation Modified human thymic stromal lymphopoietin
DK2311869T3 (da) 2002-02-01 2013-03-18 Merck Sharp & Dohme Anvendelse af pattedyrcytokinrelaterede reagenser
HRP20020453A2 (en) 2002-05-23 2003-12-31 Pliva D D 1,3-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof
CA2497884C (en) 2002-09-06 2013-10-22 Brian Varnum Therapeutic human anti-il-1r1 monoclonal antibody
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
NZ544456A (en) 2003-07-18 2009-02-28 Schering Corp Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin
PT1648998E (pt) 2003-07-18 2014-11-04 Amgen Inc Agentes de ligação específica ao factor de crescimento do hepatócito
ZA200604864B (en) 2003-12-19 2007-10-31 Genentech Inc Monovalent antibody fragments useful as therapeutics
US20050249712A1 (en) 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
AU2005277236A1 (en) 2004-08-20 2006-03-02 Amgen Inc. Methods and compositions for treating allergic inflammation
MX2007005866A (es) * 2004-11-17 2007-11-12 Amgen Inc Anticuerpos monoclonales totalmente humanos para il-13.
SG162788A1 (en) 2005-06-14 2010-07-29 Amgen Inc Self-buffering protein formulations
RU2486202C2 (ru) 2006-01-13 2013-06-27 Айрм Ллк Антитела к рецептору тимусного стромального лимфопоэтина
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
BRPI0720271A2 (pt) 2006-12-14 2014-01-28 Schering Corp Anticorpo anti-tslp projetado
CA2691157A1 (en) 2007-06-20 2008-12-24 Irm Llc Methods and compositions for treating allergic diseases
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
WO2009035577A1 (en) 2009-03-19
JP2024161358A (ja) 2024-11-19
CA2698382C (en) 2015-07-14
JP5956716B2 (ja) 2016-07-27
MX2010002590A (es) 2010-03-26
US20200071393A1 (en) 2020-03-05
PH12017501025B1 (en) 2022-10-26
CL2008002668A1 (es) 2009-08-14
US20110274687A1 (en) 2011-11-10
DK2205635T3 (en) 2016-07-18
MY150242A (en) 2013-12-31
JP2017110011A (ja) 2017-06-22
US20090238823A1 (en) 2009-09-24
IL204069A (en) 2017-03-30
SG10201506251YA (en) 2015-11-27
US10287348B2 (en) 2019-05-14
US20160152700A1 (en) 2016-06-02
HUS2200051I1 (hu) 2022-12-28
JO3351B1 (ar) 2019-03-13
LT2205635T (lt) 2016-09-26
SI2205635T1 (sl) 2016-09-30
RS54950B1 (sr) 2016-11-30
PE20110668A1 (es) 2011-10-01
TW200918554A (en) 2009-05-01
US9284372B2 (en) 2016-03-15
EP2205635A1 (en) 2010-07-14
AR068508A1 (es) 2009-11-18
KR101597371B1 (ko) 2016-02-26
JP2020058365A (ja) 2020-04-16
HK1145843A1 (zh) 2011-05-06
FR22C1059I2 (fr) 2023-12-22
IL265854A (en) 2019-06-30
JP2015091820A (ja) 2015-05-14
NL301207I2 (nl) 2023-02-02
EA201590631A1 (ru) 2016-03-31
HRP20160638T1 (hr) 2016-07-01
CN104231081A (zh) 2014-12-24
FR22C1059I1 (fr) 2023-02-03
PE20140232A1 (es) 2014-02-28
EP2205635B1 (en) 2016-05-25
CA2698382A1 (en) 2009-03-19
ES2581229T3 (es) 2016-09-02
CN101809035B (zh) 2014-07-09
JP2010538608A (ja) 2010-12-16
KR20100067660A (ko) 2010-06-21
EP2703414A1 (en) 2014-03-05
TWI449709B (zh) 2014-08-21
CY1117702T1 (el) 2017-05-17
CN101809035A (zh) 2010-08-18
JP2021191758A (ja) 2021-12-16
US20120190829A1 (en) 2012-07-26
PL2205635T3 (pl) 2016-12-30
JP2019038843A (ja) 2019-03-14
CN104231081B (zh) 2022-01-11
US8163284B2 (en) 2012-04-24
NZ583933A (en) 2012-07-27
KR20140141666A (ko) 2014-12-10
CY2022036I2 (el) 2023-03-24
TW201412774A (zh) 2014-04-01
EA022796B1 (ru) 2016-03-31
SG178781A1 (en) 2012-03-29
CL2012003245A1 (es) 2013-03-22
PH12017501025A1 (en) 2018-01-29
JP2023065375A (ja) 2023-05-12
CR20150095A (es) 2015-04-06
EP3524622A1 (en) 2019-08-14
EA201000471A1 (ru) 2010-10-29
CY2022036I1 (el) 2023-01-05
NO2022055I1 (no) 2022-12-09
AU2008300028A1 (en) 2009-03-19
IL250900A0 (en) 2017-04-30
US7982016B2 (en) 2011-07-19
ZA201001895B (en) 2011-02-23
PT2205635T (pt) 2016-07-13
AU2008300028B2 (en) 2014-12-18
HUE028361T2 (en) 2016-12-28
CR11319A (es) 2010-04-21

Similar Documents

Publication Publication Date Title
NL301207I1 (nl) tezepelumab
DE602008006301D1 (de) Koaxialnadelanordnung
BRPI0821573A2 (pt) benzofuropirimidonas
ATE501136T1 (de) Imidazopyridinone
DK2159224T3 (da) Bromphenylsubstituerede thiazolyldihydropyrimidiner
ATE514696T1 (de) Diphenyl-dihydro-imidazopyridinone
DE112008003636A5 (de) Mehrzuggruppierer
DE602008002772D1 (de) Polyvinylpyrrolidonpulverzusammensetzungen
DE502007001207D1 (de) Elektrosaugkopf
BRPI0811451A2 (pt) Exopolissacarídeo
DE602008000923D1 (de) Einzelwaferätzgerät
BRPI0814519A2 (pt) Organopolissiloxano
DE602008000749D1 (de) Buschschneider
BRPI0812840A2 (pt) 2-imidazolinas
BRPI0815547A2 (pt) Depsipeptídeos cícliocos
AT505058A3 (de) Türschliesssystem
DE602008001234D1 (de) Bandmaterialzuführvorrichtung
BRPI0812994A2 (pt) Microbiocidas
DE602008005950D1 (de) Münzvereinzeler
DE602008005589D1 (de) Rliganden
DE112008001216A5 (de) Magnetronplasmaanlage
DE502008001694D1 (de) Mitfahrhubwagen
DE112008003094A5 (de) Geomatte
DE602008001674D1 (de) Wimpernwickler
DE602008006131D1 (de) Schussfadeneintragdüse